The data showed that meR342-EZH2 was highly expressed in breast cancer patients with high PRMT1 expression (Fig. 6A), whereas pT311-EZH2 was expressed at low levels in breast cancer tissues with high PRMT1 expression (Fig. 6B). This evidence concerns the gene PRMT1 and breast carcinoma.